Inoue S - Search Results

1

Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy.

Yoshikawa T, Wu Z, Inoue S, Kasuya H, Matsushita H, Takahashi Y, Kuroda H, Hosoda W, Suzuki S, Kagoya Y. Yoshikawa T, et al. Among authors: inoue s. Blood. 2022 Apr 7;139(14):2156-2172. doi: 10.1182/blood.2021012714. Blood. 2022. PMID: 34861037 Free article.

2

CD83 expression characterizes precursor exhausted T cell population.

Wu Z, Yoshikawa T, Inoue S, Ito Y, Kasuya H, Nakashima T, Zhang H, Kotaka S, Hosoda W, Suzuki S, Kagoya Y. Wu Z, et al. Among authors: inoue s. Commun Biol. 2023 Mar 11;6(1):258. doi: 10.1038/s42003-023-04631-6. Commun Biol. 2023. PMID: 36906640 Free PMC article.

3

Epigenetic profiles guide improved CRISPR/Cas9-mediated gene knockout in human T cells.

Ito Y, Inoue S, Nakashima T, Zhang H, Li Y, Kasuya H, Matsukawa T, Wu Z, Yoshikawa T, Kataoka M, Ishikawa T, Kagoya Y. Ito Y, et al. Among authors: inoue s. Nucleic Acids Res. 2024 Jan 11;52(1):141-153. doi: 10.1093/nar/gkad1076. Nucleic Acids Res. 2024. PMID: 37985205 Free PMC article.

4

Gene editing technology to improve antitumor T-cell functions in adoptive immunotherapy.

Ito Y, Inoue S, Kagoya Y. Ito Y, et al. Among authors: inoue s. Inflamm Regen. 2024 Mar 11;44(1):13. doi: 10.1186/s41232-024-00324-7. Inflamm Regen. 2024. PMID: 38468282 Free PMC article. Review.

5

High CD62L expression predicts the generation of chimeric antigen receptor T cells with potent effector functions.

Kasuya H, Zhang H, Ito Y, Yoshikawa T, Nakashima T, Li Y, Matsukawa T, Inoue S, Kagoya Y. Kasuya H, et al. Among authors: inoue s. Int Immunol. 2024 Mar 22:dxae015. doi: 10.1093/intimm/dxae015. Online ahead of print. Int Immunol. 2024. PMID: 38517027

6

Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cells.

Yoshikawa T, Ito Y, Wu Z, Kasuya H, Nakashima T, Okamoto S, Amaishi Y, Zhang H, Li Y, Matsukawa T, Inoue S, Kagoya Y. Yoshikawa T, et al. Among authors: inoue s. Cell Rep Med. 2024 Apr 16:101526. doi: 10.1016/j.xcrm.2024.101526. Online ahead of print. Cell Rep Med. 2024. PMID: 38670095 Free article.

7

Strategic Approach to Heterogeneity Analysis of Cutaneous Adnexal Carcinomas Using Computational Pathology and Genomics.

Nishimura Y, Ryo E, Inoue S, Kawazu M, Ueno T, Namikawa K, Takahashi A, Ogata D, Yoshida A, Yamazaki N, Mano H, Yatabe Y, Mori T. Nishimura Y, et al. Among authors: inoue s. JID Innov. 2023 Sep 9;3(6):100229. doi: 10.1016/j.xjidi.2023.100229. eCollection 2023 Nov. JID Innov. 2023. PMID: 37965425 Free PMC article.

8

Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations.

Inoue S, Hirota Y, Ueno T, Fukui Y, Yoshida E, Hayashi T, Kojima S, Takeyama R, Hashimoto T, Kiyono T, Ikemura M, Taguchi A, Tanaka T, Tanaka Y, Sakata S, Takeuchi K, Muraoka A, Osuka S, Saito T, Oda K, Osuga Y, Terao Y, Kawazu M, Mano H. Inoue S, et al. Nat Commun. 2019 Dec 19;10(1):5785. doi: 10.1038/s41467-019-13708-y. Nat Commun. 2019. PMID: 31857578 Free PMC article.

9

KRAS mutations in uterine endometrium are associated with gravidity and parity.

Inoue S, Yoshida E, Fukui Y, Ueno T, Kawazu M, Takeyama R, Ikemura M, Osuga Y, Terao Y, Hirota Y, Mano H. Inoue S, et al. Cell Death Dis. 2020 May 11;11(5):347. doi: 10.1038/s41419-020-2559-0. Cell Death Dis. 2020. PMID: 32393751 Free PMC article. No abstract available.

10

Dialumene-Mediated Production of Phosphines through P4 Reduction.

Xu H, Roy MMD, Kostenko A, Kelly JA, Fujimori S, Inoue S. Xu H, et al. Among authors: inoue s. Angew Chem Int Ed Engl. 2024 May 19:e202404532. doi: 10.1002/anie.202404532. Online ahead of print. Angew Chem Int Ed Engl. 2024. PMID: 38763910

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

5,803 results

Search Page